Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Arch Biopartners Inc. (ACHFF : OTC)

• Company Description    Arch Biopartners Inc. is a clinical stage company developing new drug candidates for treating organ damage caused by inflammation. Arch Biopartners Inc. is based in TORONTO. Number of Employees: 6

• Price / Volume Information    Yesterday's Closing Price: $1.24 Daily Weekly Monthly 20 Day Moving Average: 14,344 shares Shares Outstanding: 65.91 (millions) Market Capitalization: $81.72 (millions) Beta: 1.65 52 Week High: $1.52 52 Week Low: $0.89 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -6.77% -10.26% 12 Week -2.36% -17.87% Year To Date -8.15% -13.98%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 545 King St W. - Toronto,A6 M5X 1A1 CAN ph: 64-7428-7031 fax: - None http://www.archbiopartners.com

• General Corporate Information    Officers Richard Muruve - Chief Executive Officer and Director Andrew Bishop - Chief Financial Officer and Director Richard Rossman - Director Claude Allary - Director Daniel Muruve - Chief Science Officer Peer Information Arch Biopartners Inc. (GSAC) Arch Biopartners Inc. (CASI) Arch Biopartners Inc. (ALCD.) Arch Biopartners Inc. (OMNN) Arch Biopartners Inc. (CGPI.) Arch Biopartners Inc. (CATX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: 03938C104 SIC: 8731 Fiscal Year Fiscal Year End: September Last Reported Quarter: 03/01/25 Next Expected EPS Date: - Share - Related Items Shares Outstanding: 65.91 Most Recent Split Date: (:1) Beta: 1.65 Market Capitalization: $81.72 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: -

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: - Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 0.00% vs. Previous Quarter: -% Sales Growth vs. Year Ago Period: -61.64% vs. Previous Quarter: -% ROE 06/30/25 - - 03/31/25 - - 12/31/24 - - ROA 06/30/25 - - 03/31/25 - -296.58 12/31/24 - -293.86 Current Ratio 06/30/25 - - 03/31/25 - - 12/31/24 - 0.11 Quick Ratio 06/30/25 - - 03/31/25 - - 12/31/24 - 0.11 Operating Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Pre-Tax Margin 06/30/25 - - 03/31/25 - - 12/31/24 - -180.01 Book Value 06/30/25 - - 03/31/25 - - 12/31/24 - -0.05 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Capital 06/30/25 - - 03/31/25 - - 12/31/24 - -

Powered by Zacks Investment Research ©